CTRI/2020/12/029615尚未招募未知
Efficacy of Remdesivir versus Remdesivir plus Tocilizumab in moderate to severe COVID-19 patients, admitted in the CCU of a tertiary care hospital in West Bengal
Dr Swati Datta0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with moderate to severe COVID-19 disease with following criteria :
- •1. Age >18 years
- •2. Laboratory confirmed COVID-19 patients
- •3. SpO2 94%
- •4. Patients on different modalities of oxygen therapy
- •5. Patients with radiologically confirmed pneumonia
- •6. ARDS / Acute Respiratory Failure
- •Presence of raised inflammatory markers e.g. CRP, ferritin, IL-6
排除标准
- •Patients with moderate to severe COVID-19 disease with following criteria :
- •1. Pregnancy or breast feeding
- •2. Serum alanine aminotransferase(ALT) or aspartate aminotransferase (AST) >5 times the upper limit of normal (ULN)
- •3. Known severe renal impairment (eGFR ï?¼30 ml/min/1.73 m2 or on continuous RRT (hemodialysis, peritoneal dialysis)
- •4. Known severe allergic reactions to tocilizumab or other monoclonal antibodies
- •5. Known hypersensitivity to remdesivir
- •6. Treatment with immunosuppressive or immunomodulatory therapy (including tocilizumab) within the past 3 months
- •7. Absolute neutrophil count (ANC) < 1000/uL at screening
- •8. Clinical evidence of active tuberculosis or blood culture proven active secondary infections
- •9. Participating in other drug clinical trials
研究者
相似试验
招募中
3 期
Efficacy of Remdesivir in Comparison with Interferon Beta-1 a and Remdesivir in the Treatment of Covid 19IRCT20200721048159N4Vice Chancellor for Research and Technology of Lorestan University of Medical Sciences100
招募中
2 期
Effect of Tofacitinib in treatment of Covid-19IRCT20200426047212N2Ahvaz University of Medical Sciences60
招募中
2 期
Evaluating the effects of remdesivir in severe COVID-19 in hospitalized patientsIRCT20151227025726N28Shahid Beheshti University of Medical Sciences120
招募中
2 期
Effect of tofacitinib in COVID-19virus identifiedCondition 1: COVID-19. Condition 2: COVID-19.virus not identifiedClinically-epidemiologically diagnosed COVID-19Probable COVID-19Suspected COVID-19U07.1U07.2IRCT20200329046892N2Rasht University of Medical Sciences60
招募中
3 期
Assessment of utility of Remdesivir in Patients with Acute Kidney Injury or Cronic Kidney Disease in admitted COVID-19 patientsCondition 1: COVID-19. Condition 2: Acute Kidney Injury. Condition 3: Chronic Kidney Disease.Coronavirus infection, unspecifiedAcute kidney failureChronic kidney disease (CKD)B34.2IRCT20210709051824N1Men's Health and Reproductive Health Research Center(MHRHRC)100